著者: AbdallahMennatallah, HamedMostafa M, FrakolakiEfseveia, KatsamakasSotirios, VassilakiNiki, BartenschlagerRalf, ZoidisGrigoris, HirschAnna K H, Abdel-HalimMohammad, AbadiAshraf H

原題: Redesigning of the cap conformation and symmetry of the diphenylethyne core to yield highly potent pan-genotypic NS5A inhibitors with high potency and high resistance barrier.

著者: Abdel KarimShereen E, YoussefYoussef H, Abdel-HalimMohammad, FrakolakiEfseveia, VassilakiNiki, ZoidisGrigoris, AhmedNermin S, AbadiAshraf H

原題: Symmetric benzidine derivatives as anti-HCV agents: Insight into the nature, stereochemistry of the capping amino acid and the size of the terminal capping carbamates.

著者: ElHefnawiMahmoud, JoEunji, TolbaMahmoud M, FaresMohamed, YangJaewon, ShahbaazMohd, WindischMarc P

原題: Drug repurposing through virtual screening and in vitro validation identifies tigecycline as a novel putative HCV polymerase inhibitor.

著者: JockuschSteffen, TaoChuanjuan, LiXiaoxu, ChienMinchen, KumarShiv, MorozovaIrina, KalachikovSergey, RussoJames J, JuJingyue

原題: Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.

著者: RyuJi Eun, SongMyeong Jun, KimSeok-Hwan, KwonJung Hyun, YooSun Hong, NamSoon Woo, NamHee Chul, KimHee Yeon, KimChang Wook, YangHyun, BaeSi Hyun, SongDo Seon, ChangU Im, YangJin Mo, LeeSung Won, LeeHae Lim, LeeSoon Kyu, SungPil Soo, JangJeong Won, ChoiJong Young, YoonSeung Kew

原題: Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease.

著者: ChengTzu-Sheng, LiangPo-Cheng, HuangChung-Feng, YehMing-Lun, HuangChing-I, LinZu-Yau, ChenShinn-Cherng, HuangJee-Fu, DaiChia-Yen, HsiehPing-Hsin, ChuangWan-Long, YuMing-Lung

原題: Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.

著者: ZhangHuijun, ZhangXing-Quan, HuangLina S, FangXiong, KhanMohsin, XuYan, AnJing, SchooleyRobert T, HuangZiwei

原題: Synergistic inhibition of hepatitis C virus infection by a novel microtubule inhibitor in combination with daclatasvir.

著者: SokhelaSimiso, BoschBronwyn, HillAndrew, SimmonsBryony, WoodsJoana, JohnstoneHilary, AkpomiemieGodspower, EllisLeah, OwenAndrew, CasasCarmen Perez, VenterWillem Daniel Francois

原題: Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection.

著者: InduPurushothaman, RameshkumarMarimuthu Ragavan, ArunagirinathanNarasingam, Al-DhabiNaif Abdullah, Valan ArasuMariadhas, IgnacimuthuSavarimuthu

原題: Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.

著者: GurungArun Bahadur, AliMohammad Ajmal

原題: Molecular modelling studies unveil potential binding sites on human serum albumin for selected experimental and <i>in silico</i> COVID-19 drug candidate molecules.

著者: KowChia Siang, JavedAmaan, RamachandramDinesh, HasanSyed Shahzad

原題: Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trials.

著者: MeiYong-Yu, ChenYou-Ming, WuYuan-Kai, ZhangXiao-Hong, XuWen-Xiong

原題: Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection.

著者: Al-AhmariTasneem S, AlotaibiAdel F, AljasserAreej I, AljasserAbdulrahman I, EldawAnwar M, Abd-EllatifEman E

原題: The Effectiveness and Safety of Direct-Acting Antivirals in the Treatment of Hepatitis C Virus in Saudi Arabia: A Nationwide Study Based on the Saudi Ministry of Health Surveillance Data From 2017 to 2021.

著者: Fernandes CamposGuilherme Rodrigues, WardJoseph, ChenShucheng, BittarCintia, Vilela RodriguesJoão Paulo, MartinelliAna de Lourdes Candolo, SouzaFernanda Fernandes, PereiraLeonardo Régis Leira, RahalPaula, HarrisMark

原題: A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.

著者: RibeiroIsabela Gomes, Coelho-Dos-ReisJordana Grazziela Alves, FradicoJordana Rodrigues Barbosa, Costa-RochaIsmael Artur da, SilvaLuciana Diniz, FonsecaLucy Ana Dos Santos, StancioliRhaissa Carvalho Said, Teixeira-CarvalhoAndréa, Martins-FilhoOlindo Assis, TeixeiraRosângela

原題: Remodeling of immunological biomarkers in patients with chronic hepatitis C treated with direct-acting antiviral therapy.

著者: IshidaHidekazu, TakemuraMasao, SuetsuguAtsushi, NaikiTakafumi, TanakaTakuji, EiichiTomita, SerreroGinette, MatsunamiHidetoshi, YamamotoYasuko, SaitoKuniaki

原題: Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents.

著者: Di StefanoMariantonietta, IsmailMona H, LeitnerThomas, FaleoGiuseppina, Elmnan AdemSaada A, ElaminMohamed O M E, EltreifiObeidi, AlwazzehMarwan J, FioreJose R, SantantonioTeresa A

原題: Genetic Subtypes and Natural Resistance Mutations in HCV Genotype 4 Infected Saudi Arabian Patients.

著者: SonderupM W, GogelaN, NordienR, SmutsH, KorsmanS, HardieD, SpearmanC W

原題: Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.

著者: KurosakiKota, UesawaYoshihiro

原題: Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions.

著者: Perez-BernaAna J, Benseny-CasesNuria, RodríguezMaría José, ValcarcelRicardo, CarrascosaJosé L, GastaminzaPablo, PereiroEva

原題: Monitoring reversion of hepatitis C virus-induced cellular alterations by direct-acting antivirals using cryo soft X-ray tomography and infrared microscopy.

著者: MondalMilon, SarkarChandan, JamaddarSarmin, KhaliphaAbul B R, IslamMuhammad Torequl, MahafzahAzmi, MubarakMohammad S

原題: Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 Through a Molecular Docking Study.

著者: MorinSébastien, MoakHannah Barron, Bubb-HumfryesOliver, von DrehleChristian, LazarusJeffrey V, BurroneEsteban

原題: The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study.

著者: GarimellaTushar, TaoXiaolu, SimsKaren, ChangYi-Ting, RanaJignasa, MyersElsa, Wind-RotoloMegan, BhatnagarRahul, EleyTimothy, LaCretaFrank, AbuTarifMalaz

原題: Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.

著者: ParkashArit, MerchantAyesha Altaf, AhmedSyed Habib, HussainWajid, HayatMuhammad, MemonNadeem Ahmed

原題: Effectiveness And Safety Of Direct Acting Antiviral Agents In Thalassaemic Patients With Chronic Hepatitis C.

著者: YelemkoureEdwige T, YonliAlbert T, SombieHermann K, TaoIssoufou, ZouréAbdou Azaque, OuattaraAbdoul Karim, SorghoAbel P, ZongoArsène W, ZebaMoctar T A, KiendrebeogoIsabelle T, BadoProsper, KabréMadeleine K, ZohonconThéodora M, DjigmaFlorencia W, Obiri-YeboahDorcas, SimporeJacques

原題: Seroprevalence, Genotyping, and Monitoring of Hepatitis C Viral Loads in Patients on Antivirals in Burkina Faso.

著者: ThangarajuPugazhenthan, Tanguturi YellaSree Sudha, Arumugam RamamurthyVijayakumar, MuthusamySivakumar, Mohamed Thameemul AnsariLappathai Habib, NavabshanIrfan, VenkatesanSajitha

原題: Is Daclatasvir a suitable substitute for Amphotericin B in the treatment of Mucormycosis when Amphotericin B is scarce?

著者: GrushkoI P, RomanovaE B, TverdokhlebovaT I, GaponM N, VodyanitskayaS Y

原題: [Comparative evaluation of the effectiveness of narlaprevir in the composition of interferon and interferon-free treatment regimens for patients with chronic hepatitis C].